ClinicalTrials.gg
RecruitingNCT05644704Updated Oct 21, 2026

Intelligent Sports Injury Prevention and Training System

An interventional study of Lower extremity and core muscle training in Sport Injury, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to male participants aged 15 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.
Updated Oct 21, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
15 Years to 55 Years
Sex
Male
01

Study summary

Sports injuries are a very important issue for baseball players. Previous studies have found that the incidence of sports injuries faced by baseball players is continuously increasing. Sports injury rates in professional baseball, high school baseball, and college baseball players were as high as 3.6, 4.6, and 5.8 per 1,000 players, respectively. The main cause of many pitching injuries is attributed to a large number of repetitive pitches. To avoid sports injuries, it is necessary to know how to assess the risk of injury caused by repetitive pitching. Throwing is a fairly complex action that requires the coordination of the entire body. It is critical to investigate the biomechanical changes of players in order to effectively analyze such complex movements.

02

Conditions studied

  • Sport Injury

Browse trials for

03

In context

Athletic Injuries

258 studies on the registry are indexed under Athletic Injuries; 45 are open to participants now.

This study's planned enrollment of 40 is close to the median of 44 across 164 interventional studies indexed under Athletic Injuries.

Browse Athletic Injuries studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
15 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy baseball pitchers
  • Age between 15\~55 years old

Exclusion criteria

Exclusion Criteria:

  • Surgery history in pitching arm
  • Musculoskeletal disease
  • Neuromuscular disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Baseball pitcher training

    Other: Lower extremity and core muscle training

Interventions

  • OtherLower extremity and core muscle training

    Lower extremity training: single leg balance training Core muscle training: pelvic control training

06

What researchers measure

Primary outcomes

  1. Countermovement jump (CMJ)

    Test CMJ before and after training

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang SM, Chen SH, Chen HY, Huang JH, Wu YR, Hsu WL. Pelvic Control and Pelvic-Trunk Coordination as Key Determinants of Pitching Velocity in Baseball Pitchers. Orthop J Sports Med. 2025 Jul 24;13(7):23259671251350302. doi: 10.1177/23259671251350302. eCollection 2025 Jul. PubMed 40727237 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 119 non-industry interventional studies with no phase under Athletic Injuries, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 14. This study's planned 48 months is above that.

Counting every sponsor, half of 121 studies reached it within 5 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jul 2026 → Dec 2026 and completion Jul 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Dec 12, 2022
Primary completionEst.
Dec 31, 2026was Jul 2026
CompletionEst.
Dec 31, 2026was Jul 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Dec 31, 2026
Oct 21, 2026
Study completion
Jul 31, 2026→Dec 31, 2026
Oct 21, 2026
Eligibility
Minimum age 18 Years→15 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAge between 1815~55 years old
Oct 21, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40727237 ↗
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40727237 ↗
    Primary completion Jul 31, 2026→Dec 31, 2026
    Study completion Jul 31, 2026→Dec 31, 2026
    Eligibility Minimum age 18 Years→15 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge between 1815~55 years old
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05644704
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 12, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 21, 2026

Study contacts

Wei-Li Hsu, PhD
Contact
wlhsu@ntu.edu.tw
+886-2-3366-8149

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion